Physician profile
Daniel Redle
NPI 1124524897
$1,495.54
in general payments reported to CMS, 2019-2025
12 companies · $669 in 2025
The $669 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $66.33 · 2022: $14.50 · 2023: $21.22 · 2024: $724 · 2025: $669.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,253 · Education: $161.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,253.22 |
| Education | $161.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abiomed | $338.87 | 2024-2025 | Impella |
| Abbott Laboratories | $312.89 | 2021-2025 | Diamondback Coronary, Cardiomems, Thoratec Heartmate 3 Lvas Implant Kit |
| Inari Medical, INC. | $189.59 | 2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Medtronic, INC. | $161.49 | 2024 | Onyx Frontier |
| Boston Scientific Corporation | $147.79 | 2025 | Avvigo Guidance System |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $133.51 | 2025 | Lifevest |
| Teleflex LLC | $105.80 | 2025 | Turnpike |
| E.R. Squibb & Sons, L.L.C. | $29.30 | 2024 | Eliquis |
| Recor Medical INC | $24.50 | 2025 | Paradise Ultrasound Renal Denervation System |
| Atricure, INC. | $18.99 | 2024 | |
| Mannkind Corporation | $18.31 | 2025 | |
| Astrazeneca Pharmaceuticals Lp | $14.50 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Redle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.